FDA Targets Hims & Hers, Other Marketers of Unapproved GLP-1 Weight-Loss Drugs

Core Viewpoint - The FDA is taking decisive steps to restrict the use of GLP-1 active pharmaceutical ingredients in non-approved drugs [1] Group 1 - The FDA's actions indicate a regulatory tightening around GLP-1 drugs, which may impact companies involved in the development and marketing of these pharmaceuticals [1]